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SUMMARY. Infectious laryngotracheitis (ILT) is a dramatic disease of the upper respiratory 18
tract in poultry caused by a herpesvirus. In this study, we investigated the characteristics of 19
West European field isolates of infectious laryngotracheitis virus (ILTV) to gain more 20
information on their diversity. The examined 104 isolates, collected from acute outbreaks 21
during the last 35 years, originated from eight different countries: Switzerland (48), Germany 22
(21), Sweden (14), the United Kingdom (9), Italy (5), Belgium (4), Austria (2) and Norway 23
(1). Two vaccines, a chicken embryo origin (CEO) product and a tissue culture origin (TCO) 24
product, were included in the survey. Polymerase chain reaction (PCR) was performed to 25
amplify a 2.1 kb DNA fragment of ILTV using primers generated for the thymidine kinase 26
(TK) gene. After digestion of the resulting PCR products by restriction endonuclease (RE) 27
HaeIII, restriction fragment length polymorphism (RFLP) analysis was carried out. PCR 28
amplicons of three field isolates and both vaccine strains were selected for sequencing. 98 29
field isolates showed the same cleavage pattern and were identical to both vaccine strains 30
(clone 1). They differed from five Swiss isolates with identical cleavage pattern (clone 2) and 31
one Swedish isolate (clone 3). 32
The present study demonstrated that at least three clones of ILTV have been circulating in 33
Western Europe during the last 35 years. The 104 isolates analyzed showed a high genetic 34
similarity regarding the TK gene and a large majority of the field isolates (98/104) was 35
genetically related to the vaccine strains. 36
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Avian infectious laryngotracheitis (ILT) is a respiratory disease of chickens. It can also 43
affect pheasants and peacocks. Difficulty in breathing, coughing up of blood or bloody 44
mucus, swollen orbital sinuses, high morbidity (up to 100%), variable mortality and decreased 45
egg production in laying hens are characteristic of the acute form of ILT. Chronic ILT may 46
look like any other respiratory infection (1). The causative agent is Infectious47
laryngotracheitis virus (ILTV), also designated Gallid herpesvirus 1 (GaHV-1), which 48
belongs to the subfamily Alphaherpesvirinae of the family Herpesviridae (23). The genome 49
of ILTV is a linear double-stranded DNA of approximately 155 kb in size (15,20). Like other 50
herpesviruses, ILTV induces latent infections, mainly in the trigeminal ganglion (3,27). 51
Latently infected chickens are the primary source of ILT outbreaks. 52
In Switzerland, ILT is a notifiable disease since 1987. Every year five to twenty 53
outbreaks are registered. They mainly occur in small, backyard and fancy breed flocks and 54
occasionally in commercial chickens (13,14). Although live attenuated vaccines against ILT 55
are available in Europe, their application is not allowed in Switzerland. The reasons for the 56
ban of vaccination are mainly economical such as the negligible number of outbreaks, the 57
difficult diagnosis of infections in vaccinated birds and the tedious differentiation between 58
field and vaccine strains. In the majority of European countries vaccination against ILT is 59
common practice in regions with repeated ILT outbreaks, although it is known that live 60
attenuated vaccines possess considerable residual virulence, which may increase after bird-to-61
bird passage (10). 62
Due to their ability to detect acute as well as latent infections, molecular methods have 63
proven to be more sensitive than virus isolation in the identification process of ILTV64
(2,16,18,26). Detection of DNA by conventional or real-time polymerase chain reaction 65
(PCR) technique followed by restriction fragment length polymorphism (RFLP) analysis is 66
the preferred method for differentiation between field isolates and vaccine strains of ILTV67
(4,5,6,7,8,11,19,21,22,25). These techniques combined with DNA sequence analysis or 68
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cluster analyses of RFLP patterns of ILTV were used for epidemiological investigations and 69
phylogenetic studies as reported previously (6,11,19,21,22). 70
Han and Kim (12) compared several ILTV strains from Korean layer hens that 71
experienced respiratory signs and mortality between 1982 and 1998 by examining RFLP 72
patterns of the amplified TK gene and by virulence testing based on pathogenicity studies in 73
chickens. Further DNA sequencing studies allowed the authors to differentiate between field 74
isolates of high and low virulence (11). The presence of the amino acid threonine (base-triplet 75
ACG) at position 252 in the sequence of the TK gene was an indication for strains of low 76
virulence, whereas the amino acid methionine (base-triplet ATG) at the same position pointed 77
to virulent strains. The same nucleotide and amino acid sequences as the low virulent strains 78
exhibited at position 252 were previously published for the Thorne strain (GenBank accession 79
number D00565) as well as for the strain 216 (GenBank accession number L36139) with 80
1092 bp in length and for the strain 632 (GenBank accession number S83714) with 1089 bp 81
in length. 82
The objective of the present study was to characterize 104 ILTV isolates from 83
vaccinated and unvaccinated fowl with acute ILT infection by PCR/RFLP in order to 84
investigate the diversity of the strains in Western Europe during the last 35 years. 85
MATERIALS AND METHODS 86
Sources of ILTV isolates. The viruses compared in our study were isolated from 87
natural acute outbreaks of ILT in Switzerland and seven further West European countries 88
(Table 1). The analyzed 104 field isolates, collected over a period of 35 years (1973-2007), 89
originated from vaccinated and unvaccinated fowl, covering different bird species and poultry 90
production sectors. Forty-eight isolates were collected in Switzerland, including four isolates 91
from commercial chicken flocks and 44 isolates from hobby or fancy chicken flocks, which 92
are often mixed with pheasants, peacocks, quails or other exotic species. Fifty-six isolates 93
were from diagnosed ILT cases in Germany (21), Sweden (14), the United Kingdom (9), Italy 94
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(5), Belgium (4), Austria (2) and Norway (1). Irrespective of differing national control 95
programs, such as ban of vaccination (Switzerland, Sweden, Norway), eradication of affected 96
flocks (Switzerland, Sweden, Norway), selected vaccination of commercial poultry (Belgium, 97
Italy) or use of vaccines in both commercial and non-commercial poultry (Germany, United 98
Kingdom, Austria) all isolates originated from clinical outbreaks. Complete information about 99
epidemiology was only available for a part of the ILT cases; mainly it was difficult to collect 100
reliable data on the vaccination status of the investigated birds (Table 1). Two ILT vaccines, 101
Serva strain and Samberg strain, were of chicken embryo origin (CEO) (Nobilis®ILT, Intervet 102
International B.V. Boxmeer, The Netherlands) and tissue culture origin (TCO) (LT-Ivax®,103
Schering-Plough Animal Health San Augustin, Spain). The viral DNA was isolated directly 104
from the lyophilized vaccine powder. ILTV DNA of two field isolates (TW/90 and TW/91-1) 105
and two vaccine strains (CEO and TCO) from Taiwan served as reference material (4). 106
Extraction of ILTV DNA. Preparation of ILTV DNA was based on the procedures 107
described by a standard protocol of Sambrook et al. (24). 400 μl of each isolate were treated 108
with 15 μl proteinkinase K (Roche), 22.5 μl sodium dodecyl sulfate (SDS) and 22.5 μl TEN 109
buffer (Tris 100 mM, EDTA 10 mM, NaCl 1 M, pH 7.4) at 56°C for two hours. The DNA 110
was extracted twice with an equal volume of phenol, purified twice with an equal volume of 111
isoamylalcohol-chloroform (1:24), precipitated at -80°C for 30 min in 1/10 volume of 3 M 112
sodium acetate (pH 4.8) and two volumes of cold (-20°C) absolute ethanol, and then pelleted 113
by centrifugation at 13.000 rpm at 4°C for 30 min. The pellet was rinsed in cold (-20°C) 70% 114
ethanol, centrifuged at 13.000 rpm at 4°C for 15 min, air dried for 60 min, resuspended in 20 115
μl demineralized water, and stored at 4°C overnight. Serial tenfold dilutions of final DNA 116
preparation were prepared in demineralized water. From each original isolate the extraction of 117
ILTV DNA was additionally carried out using the QuickGene DNA tissue kit S developed 118
from FUJIFILM Corporation (Bucher Biotec, Switzerland) according to the manufacturer’s 119
instructions. 1 μl DNA template of each isolate obtained from the two different extraction 120
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methods was used for PCR. Hence, PCR/RFLP was performed twice for all 104 samples. The 121
reproducibility of the techniques could be verified. 122
Primer design. PCR oligonucleotide sense and antisense primers were designed by 123
Microsynth (Microsynth, Switzerland) on the basis of the published DNA sequence of the 124
Thorne strain of ILTV (GenBank accession number D00565). The primers were used to 125
amplify a 2.1 kb fragment of the ILTV genome containing the TK gene. The primers designed 126
were TK gene (sense) 5’-GCTGGGCTAAATCATCCAAG-3’ and TK gene (antisense) 5’-127
GGAAGCGGAACATTACGAAC-3’. 128
Polymerase chain reaction (PCR). Hot start PCR amplification was performed using a 129
DNA thermocycler GeneAmp® PCR System 2400 (Perkin Elmer). The reaction mixture (25 130
μl) consisted of 1 μl DNA template and 24 μl master mix containing 1x PCR buffer with 1.5 131
mM MgCl2, 200 μM of each dNTP, 200 mM of each primer, and HotStarTaq DNA 132
polymerase (HotStarTaq Master Mix Kit, Qiagen). Phosphate-buffered saline (PBS) served as 133
process control. The ILTV strain T 322/04 (isolate of a one year old cock with ILT infection 134
diagnosed in 2004 by serology, histology and observed pock lesions after propagation in the 135
chorioallantoic membrane (CAM) of embryonated chicken eggs) was used as a positive 136
control. A negative control (master mix with demineralized water instead of template DNA) 137
was also included. The condition for PCR reaction was: 35 cycles of 95°C for 15 min 138
(activation of DNA polymerase), 94°C for 1 min (denaturation), 56°C for 30 s (annealing), 139
72°C for 1 min (extension), followed by 1 cycle of 72°C for 5 min (final extension). The 140
samples were cooled to 4°C and stored at 4°C. Following amplification, 10 μl of each PCR 141
product was examined by electrophoresis (70 V for 1 hour) in a 1% agarose gel (Agarose 142
Standard Eurobio) in 1x TAE buffer (Tris-acetate 40 mM, EDTA 2 mM, pH 8.0) containing 143
ethidium bromide (3 μl/100 ml). The size of PCR products was determined by comparison 144
with a molecular weight marker (1 kb DNA ladder, BioConcept), and DNA bands were 145
visualized under UV-illumination. 146
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Restriction endonuclease (RE) digestion and restriction fragment length 147
polymorphism (RFLP) analysis. 15 μl of each amplification product was digested by 1 μl of 148
tetranucleotide-recognizing RE HaeIII (Roche) using 10 μl RE buffer M supplied by the 149
manufacturer in a final volume of 100 μl at 37°C for one hour. The digested DNA was 150
precipitated, pelleted by centrifugation, rinsed, centrifuged again, and air dried, as described 151
above, resuspended in 10 μl demineralized water and stored at 4°C for 40 min. DNA 152
fragments were separated by electrophoresis (70 V for 2 hours) in a 2% agarose gel (Agarose 153
Standard Eurobio) in 1x TAE buffer (Tris-acetate 40 mM, EDTA 2 mM, pH 8.0) containing 154
ethidium bromide (3 μl/100 ml) to stain the DNA. The size of DNA RE fragments was 155
compared with a molecular weight marker (peqGOLD 100 bp DNA-Leiter Plus, PEQLAB, 156
Germany) ranging from 100 bp to 3000 bp bands. Bands were visualized using UV-157
transillumination (Alpha Innotech, CA, USA) and photographed. 158
Sequencing. Sequencing of the 2.1 kb DNA fragment of the three field isolates CH04, 159
CH95 and S04 with different RFLP patterns and the two vaccine strains was performed. The 160
amplified PCR products were purified using High Pure PCR Product Purification Kit (Roche) 161
according to manufacturer’s instructions. Purified DNA was sent to Microsynth Corporation 162
(Microsynth, Switzerland) for sequencing. The nucleotide sequences were determined for 163
both strands, checking them five times. The sequences were assembled using software 164
Lasergene SeqMan7.2 (DNASTAR). For highlighting open reading frames (ORF) and 165
comparing the identity of the sequencing products, the sequences were analyzed using 166
available computer software (http://seqtool.sdsc.edu/CGI/BW.cgi and 167
http://www.ncbi.nlm.nih.gov/blast/). Alignment of the nucleotide and predicted amino acid 168
sequences for the TK protein of the Thorne strain, the three field isolates CH04, CH95 and 169
S04 and the two vaccine strains CEO and TCO were performed using EXPASY molecular 170
tools (http://www.expasy.ch). 171
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GenBank accession numbers. The TK sequences presented in this study have been 172
submitted to GenBank under accession numbers ranging from EU360946 to EU360950. 173
RESULTS174
PCR amplification of a 2.1 kb region of the ILTV genome containing the TK gene. 175
All PCR products of the ILTV field isolates and vaccine strains analyzed in our study resulted 176
in one DNA band of approximately 2.1 kb (Fig. 1). The PCR products of three field isolates 177
of ILTV (two from Switzerland, one from Southern Germany) in comparison with molecular 178
weight standards are presented in Fig. 1. 179
All ILTV isolates analyzed by use of PCR were detected. The primer set, generated for 180
TK gene of the Thorne strain of ILTV, was shown to be specific for ILTV. In our preliminary 181
studies it did not amplify other viruses from avian sources and in particular no other 182
herpesviruses such as Marek’s disease virus or pigeon herpesvirus. 183
Comparison of RFLP patterns generated by HaeIII-digestion of the 2.1 kb PCR 184
product. Three different RFLP patterns were observed (Fig. 2). Forty-three Swiss field 185
isolates and 55 field isolates from the other seven West European countries as well as the two 186
vaccine strains produced identical RFLP patterns (classified as clone 1; Fig. 2, lanes 1, 4 and 187
5). Twenty clone 1 field isolates originated with certainty from unvaccinated birds, 61 isolates 188
were from birds which were highly suspicious for not being vaccinated and 17 isolates from 189
birds with high suspicion for being vaccinated. Clone 1 spread among birds in Swiss backyard 190
flocks (39/44) and in Swiss commercial chicken flocks (4/4) as well as in hobby poultry 191
farming and the poultry industry in Germany (21/21), Sweden (13/14), the United Kingdom 192
(9/9), Italy (5/5), Belgium (4/4), Austria (2/2) and Norway (1/1) during the last 35 years. Of 193
the 98 clone 1 isolates 66 originated from backyard flocks and 32 were obtained from 194
commercial poultry. No significance for clone 1 was found between commercial poultry and 195
backyard flocks (p > 0.05, chi-square test). Five Swiss field isolates (clone 2; Fig. 2, lane 2) 196
and one Swedish field isolate (clone 3; Fig. 2, lane 3) differed from the other field isolates and 197
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the vaccine strains (clone 1; Fig. 2, lanes 1, 4 and 5). Only clone 1 has been circulating for 35 198
years in West European countries and was widespread in both poultry sectors, in commercial 199
and in non-commercial poultry. The five Swiss clone 2 isolates from birds with high 200
suspicion for not being vaccinated and the one Swedish clone 3 isolate from with certainty 201
unvaccinated birds were limited either in regional spread or number of cases and therefore did 202
not develop an epizootic character. Both clones were found in non-commercial poultry. 203
Different clone patterns and origin of the field isolates and vaccine strains are presented in 204
Table 2. Results of the positions of restriction sites for HaeIII (GG:CC) of the sequences of 205
the three isolates CH04, CH95 and S04 and the two vaccine strains CEO and TCO for the TK206
protein are presented in Table 3. 207
DNA sequence analysis of the 2.1 kb PCR product of three field isolates and two 208
vaccine strains of ILTV. All strains selected for sequencing were 2167 bp in length. 209
Computer analysis revealed the presence of one complete 1089 bp ORF for each amplicon 210
and online BLAST search showed 99% nucleotide identity between the ORF of each of the 211
five amplicons and the DNA sequence from the region of the TK gene of ILTV as determined 212
by Griffin and Boursnell (9) from the Thorne strain which consists of 1092 bp. Results of the 213
positions of nucleotide and amino acid changes of the sequences of the three isolates CH04, 214
CH95 and S04 and the two vaccine strains CEO and TCO for the TK protein are presented in 215
Table 3. The nucleotide sequences of the two vaccine strains were identical. The Swiss field 216
isolate CH04 differed from the vaccine strains in one nucleotide at position 540 (C to T). This 217
led to no change in amino acid. The same nucleotide substitution was found in the Swedish 218
field isolate S04. Additionally, in the field isolate S04 another nucleotide mutation was 219
present at position 411 (A to G) and led to the sequence GGCC and a unique RFLP pattern 220
after digestion with HaeIII (Fig. 2, lane 3). Again no change in amino acid occurred. The 221
Swiss field isolate CH95 differed from the vaccine strains by four nucleotides at position 123 222
(T to C), at position 141 (G to A), at position 594 (A to C) and at position 755 (C to T). Due 223
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to the change of A to C at position 594 an additional band was visible after HaeIII-digestion224
and RFLP analysis (Fig. 2, lane 2). The nucleotide change at position 755 (C to T) caused a 225
change in amino acid. Methionine (ATG) replaced threonine (ACG) at position 252 in the 226
field isolate CH95. 227
DISCUSSION 228
In this study, we investigated the characteristics of 104 field isolates of ILTV from eight 229
West European countries by PCR/RFLP and sequence analysis. The isolates, collected over a 230
period of 35 years (1973-2007) showed three different cleavage patterns (clone 1, 2 and 3). 231
Molecular methods to identify and differentiate ILTV strains were developed by Clavijo 232
and Nagy (5). They were able to separate a virulent field strain from three vaccine strains by 233
use of PCR/RFLP. Using the same technique, Chang et al. (4) investigated field isolates 234
collected from outbreaks of acute ILT in chickens in Taiwan and discriminated field isolates 235
from vaccine strains. They were able to differentiate three CEO vaccines with identical RE 236
cleavage products from two of four field isolates. The other two field isolates remained 237
indistinguishable from the CEO vaccines but differed from a TCO vaccine. Their strains 238
served as reference material and we could confirm the two different RFLP patterns and the 239
diversity of the CEO and TCO vaccine strains. In our study, the TCO vaccine from Spain and 240
the CEO vaccine from the Netherlands showed the same RFLP pattern (Fig. 2, lanes 4 and 5) 241
and their nucleotide sequences were identical. They matched the virulent field strain 632 242
(GenBank accession number S83714), but differed from the isolate CH04 and the isolate S04 243
in one and two nucleotides, respectively. Han and Kim (11) also analyzed six commercial 244
vaccines originating from chicken embryo and reported that the RFLP patterns of the TK gene 245
of low virulence strains were identical to those of the vaccine strains. According to their 246
sequence analyses of the low virulence and the vaccine strains, threonine was the amino acid 247
at position 252. In our study, sequencing of the TK gene of the Swiss field isolate CH95 248
resulted in four nucleotides differing from the two vaccine strains (CEO and TCO). 249
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Interestingly, the changes in nucleotides were identical to three strains sequenced and 250
specified as virulent by Han and Kim (11), including Korean field isolates of ILTV from 251
vaccinated and unvaccinated chickens. 252
Our study showed that the TK gene of field clone 1 and clone 3 viruses (CH04 and S04) 253
shared the amino acid threonine at position 252 with Korean field isolates previously 254
identified as low virulence strains. On the other hand, the amino acid change in field clone 2 255
viruses (CH95) with a methionine at position 252 was equivalent with virulent strains from 256
Korea. The sequence of vaccine clone 1 viruses with a threonine at position 252 matched 257
sequences of ILTV strains either of high virulence, such as strain 632 from the United States 258
as published by Keeler et al. (17) and of low virulence, such as Korean strains as described by 259
Han and Kim (11). However, the sequence analysis of the TK gene of ILTV alone cannot be 260
used to differentiate between ILTV of high and low virulence. It is highly likely that other in 261
this study unexamined genes in the large genome of ILTV play a role in virulence. 262
Although we investigated a considerable number of Swiss ILTV isolates (48 isolates) 263
covering different bird species and poultry production sectors the full comparison of the RE 264
cleavage products showed only two different RFLP patterns. Forty-three out of 48 isolates 265
from Switzerland belonged to clone 1. Five Swiss isolates could be grouped to clone 2, which 266
was found repeatedly in fancy breed flocks between 1973 and 1995, but never detected in 267
commercial poultry. Some clone 1 isolates from Switzerland may have also originated from 268
illegally imported vaccinated backyard chickens of surrounding neighboring countries such as 269
Germany and France. Therefore, we decided to analyze approximately an equal number of 270
ILTV isolates from other European countries (56 isolates). Clone 1 was found in 55 isolates, 271
clone 2 was not detected and clone 3 was only isolated from a Swedish non-commercial 272
poultry of an outbreak in 2004. In the isolates analyzed (n = 104), originating from backyard 273
flocks (n = 72) and commercial poultry (n = 32), clone 1 was equally represented with 92% 274
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(66/72) and 100% (32/32), respectively. In our study, the two vaccine strains from different 275
origins produced RFLP patterns of clone 1. 276
Vaccination status of the birds from which ILTV was isolated and analyzed is shown in 277
Table 1. As has been proved, only 21 of all examined 104 isolates and only 20 out of the 98 278
(20%) field clone 1 isolates with certainty came from birds of unvaccinated flocks. We 279
speculate that some of the field clone 1 viruses from flocks of uncertain vaccination status 280
were re-isolated vaccines, especially based on the fact that vaccination is allowed in other 281
West European countries surrounding Switzerland. 282
It is a fact that new clones, such as clone 2 and clone 3 in our study, primarily 283
originated from non-commercial poultry. The latency and longer circulation of the virus in 284
non-commercial poultry seems to favor the development of new clones, whereas in 285
commercial poultry quicker and/or stricter control measures such as eradication, vaccination, 286
all in-, all out-management limit the duration of viral circulation in birds. 287
The present study showed that at least three clones of ILTV have been circulating in 288
Western Europe during the last 35 years. The most relevant part of this study was that a large 289
majority of the West European field isolates analyzed, 98 out of 104 isolates, were genetically 290
related to the vaccine strains. 291
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Figure captions: 388
Fig. 1. Agarose gel electrophoresis of PCR amplification products of two ILT isolates 389
from Switzerland and one ILT isolate from Southern Germany, with primers specific to the 390
TK gene of ILTV. PCR was performed as described in the text. Lane M: 1 kb DNA ladder 391
(bands of 500, 1000, 1500, 2000, 3000, 4000, 5000, 6000, 8000 and 10000 bp are shown in 392
the far left lane), lanes 1 and 2: ILT field isolates from Switzerland, lane 3: ILT field isolate 393
from Southern Germany, lane 4: process control, lane 5: positive control and lane 6: negative 394
control.395
Fig. 2. Agarose gel electrophoresis of DNA RE fragments of the 2.1 kb PCR 396
amplification product of three ILT field isolates and two ILT vaccine strains, digested by RE 397
HaeIII. RFLP analysis was performed as described in the text. Lane M: 100 bp DNA ladder 398
(bands of 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1200, 1500, 2000 and 3000 bp 399
are shown in the far left lane), lane 1: ILT field isolate CH04, lane 2: ILT field isolate CH95, 400
lane 3: ILT field isolate S04, lane 4: ILT vaccine strain CEO and lane 5: ILT vaccine strain 401
TCO, digested by HaeIII.402


Table 1. Origin, number, year of isolation, husbandry and vaccination status of ILTV  isolates analyzed.
Country Year of isolation
Switzerland 48 1973 - 2007 44B   4A
Germany 21 1994 - 2005   8B 13C
Sweden 14 1998 - 2006 14A   0
United Kingdom 9 in the 1980s   0   9B
Italy 5 1998 and 1999   2B   3C
Belgium 4 1976, 2004 and 2005   3B   1C
Austria 2 2007   0   2A
Norway 1 1998   1A   0
Totals 104 72 32
AIsolates from with certainty unvaccinated birds.
BIsolates from birds with high suspicion for not being vaccinated.
CIsolates from birds with high suspicion for being vaccinated. 
Number of isolates
Non-commercial poultry Commercial poultry
Husbandry

Table 2. Results of RFLP analysis of the TK  gene of ILTV  field isolates and vaccine strains after Hae III-digestion.
ILTV
Isolates
Switzerland 48 43 5A 0
Germany 21 21 0 0
Sweden 14 13 0 1B
United Kingdom 9 9 0 0
Italy 5 5 0 0
Belgium 4 4 0 0
Austria 2 2 0 0
Norway 1 1 0 0
Vaccines
CEO 1 1 0 0
TCO 1 1 0 0
Totals 106 100 5 1
AClone 2 was isolated from non-commercial poultry between 1973 and 1995. The birds were highly suspicious for not being vaccinated.
BClone 3 was isolated from unvaccinated non-commercial poultry in 2004.
Clone 1 Clone 2 Clone 3Number of isolates and vaccines

Clone Clone 2 Clone 3
Strain sequenced CH04 CEO TCO CH95 S04
GenBank accession number EU360946 EU360949 EU360950 EU360947 EU360948
Positions of nucleotide changes
123 T T T C T
141 G G G A G
411 A A A A G
540 T C C C T
594 A A A C A
755 C C C T C
Position of amino acid change
252 Thr Thr Thr Met Thr
Positions of restriction sites for Hae III (GG:CC) 004:005 004:005 004:005 004:005 004:005
108:109 108:109 108:109 108:109 108:109
411:412
592:593
959:960 959:960 959:960 959:960 959:960
Clone 1
Table 3. Summarized results of the positions of nucleotide and amino acid changes and the restriction sites for Hae III
of the sequences of the isolates CH04, CH95 and S04 and the vaccines CEO and TCO for the TK protein.
